Bristol Myers and Celgene are being sued in an antitrust suit, alleging they used fraud, sham litigation, and reverse ...

Cigna sued Bristol Myers Squibb on Tuesday, accusing the drugmaker of violating U.S. antitrust law by keeping generic ...

Two months after Bristol Myers Squibb fended off a lawsuit which accused the drugmaker of using illegal tactics to protect ...

Celgene will initially take the lead on the clinical development programme, which will focus on the use of MEDI4736 as both a monotherapy and in combination with the US firm's portfolio of cancer ...

Celgene thanked the woman who had the idea to use thalidomide as a treatment for multiple myeloma in its annual report, but says she isn't owed a dime for discovering the $2.2 billion-a-year ...

This time, Celgene has picked on the wrong victim, and if you read between the lines of Judge Faith Hochberg's ruling (which keeps the case alive by as thinly contrived a judicial thread as I've ...

Celgene funded more studies combining thalidomide with a treatment for myeloma, and it became the standard of care for the blood cancer. At first, Beth Wolmer had a warm relationship with the company.

"Celgene is buying 9.1 million shares of Juno at $93 per share -- a 102% premium to Juno's closing price of $46.30." -- The Street. Even I bit initially before realizing the stated share price was ...

Cancer-drug company Celgene Corp. said it will pay $7.2 billion for biotech company Receptos Inc. in a bid to move deeper into the multibillion-dollar market for autoimmune diseases.

Celgene just acquired immunotherapy biotech Juno Therapeutics in a $9 billion dollar deal. The deal will allow Celgene to compete in a space already occupied by Novartis and Gilead as they vie for ...

Cigna sued Bristol Myers Squibb on Tuesday, accusing the drugmaker of violating U.S. antitrust law by keeping generic ...